Cargando…
Challenges in the Evaluation of Emerging Highly Specialised Technologies: Is There a Role for Living HTA?
There is currently deep uncertainty about the clinical benefits and cost effectiveness of highly specialised technologies (HSTs), like gene and cell therapies. These treatments are novel, typically have high upfront costs, the patient populations are small and heterogenous, there is minimal informat...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628011/ https://www.ncbi.nlm.nih.gov/pubmed/37824056 http://dx.doi.org/10.1007/s40258-023-00835-3 |